TR201908199T4 - HPV'ye karşı aşılar. - Google Patents
HPV'ye karşı aşılar. Download PDFInfo
- Publication number
- TR201908199T4 TR201908199T4 TR2019/08199T TR201908199T TR201908199T4 TR 201908199 T4 TR201908199 T4 TR 201908199T4 TR 2019/08199 T TR2019/08199 T TR 2019/08199T TR 201908199 T TR201908199 T TR 201908199T TR 201908199 T4 TR201908199 T4 TR 201908199T4
- Authority
- TR
- Turkey
- Prior art keywords
- vaccines against
- hpv
- methods
- peptides
- relates
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 3
- 108010041986 DNA Vaccines Proteins 0.000 abstract 2
- 229940021995 DNA vaccine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578542P | 2011-12-21 | 2011-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201908199T4 true TR201908199T4 (tr) | 2019-06-21 |
Family
ID=47471832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/08199T TR201908199T4 (tr) | 2011-12-21 | 2012-12-20 | HPV'ye karşı aşılar. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9901635B2 (enExample) |
| EP (2) | EP2793937B1 (enExample) |
| JP (1) | JP6258864B2 (enExample) |
| KR (1) | KR102057265B1 (enExample) |
| CN (1) | CN104039833B (enExample) |
| AU (1) | AU2012356969B2 (enExample) |
| BR (1) | BR112014015016B1 (enExample) |
| CA (1) | CA2858963C (enExample) |
| DK (1) | DK2793937T3 (enExample) |
| ES (1) | ES2730718T3 (enExample) |
| HU (1) | HUE043361T2 (enExample) |
| IL (1) | IL233217B (enExample) |
| PT (1) | PT2793937T (enExample) |
| RU (1) | RU2644201C2 (enExample) |
| TR (1) | TR201908199T4 (enExample) |
| WO (1) | WO2013092875A1 (enExample) |
| ZA (1) | ZA201404516B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014140176A1 (en) * | 2013-03-15 | 2014-09-18 | Vaccibody As | Targeting vaccines for veterinary use |
| US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
| WO2016024255A1 (en) | 2014-08-15 | 2016-02-18 | Genexine, Inc. | Methods of treating cervical cancer |
| AU2016309743B2 (en) * | 2015-08-20 | 2019-02-07 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV18 vaccines |
| CA3008437A1 (en) | 2016-01-08 | 2017-07-13 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
| EP3678699A1 (en) * | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
| US12268736B2 (en) | 2017-09-07 | 2025-04-08 | University Of Oslo | Vaccine molecules |
| AU2021252155A1 (en) | 2020-04-09 | 2022-12-08 | Nykode Therapeutics ASA | Individualized therapeutic anticancer vaccine |
| CN115551547A (zh) | 2020-04-24 | 2022-12-30 | 格纳西尼有限公司 | 宫颈癌治疗方法 |
| JP2023524054A (ja) | 2020-05-01 | 2023-06-08 | ナイコード セラピューティクス アルメン アクスイェ セルスカプ | ベータコロナウイルスの予防と治療 |
| CA3212592A1 (en) | 2021-03-26 | 2022-09-29 | Agnete Fredriksen | Therapeutic combination for treating cancer |
| EP4333881A1 (en) | 2021-05-03 | 2024-03-13 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| US20250195632A1 (en) | 2021-05-10 | 2025-06-19 | Nykode Therapeutics ASA | Tolerance-inducing constructs and composition and their use for the treatment of immune disorders |
| MX2023013308A (es) | 2021-05-10 | 2024-02-14 | Nykode Therapeutics ASA | Co-expresion de construcciones y compuestos inmunoinhibidores. |
| IL308310A (en) | 2021-05-10 | 2024-01-01 | Nykode Therapeutics ASA | Co-expression of immune-stimulating structures and compounds |
| WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| US20250288654A1 (en) | 2021-05-10 | 2025-09-18 | Nykode Therapeutics ASA | Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders |
| WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
| EP4426344A1 (en) | 2021-11-03 | 2024-09-11 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| BR0314529A (pt) * | 2002-10-03 | 2005-08-09 | Wyeth Corp | Polipeptìdeos de papilomavìrus humano e composições imunogênicas |
| US8932603B2 (en) | 2003-02-25 | 2015-01-13 | Vaccibody As | Modified antibody |
| EP1576967B1 (en) * | 2004-03-18 | 2007-09-12 | Institut Pasteur | Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof |
| EP1846026A4 (en) | 2005-01-26 | 2008-07-02 | Univ Johns Hopkins | ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN |
| CN102985109B (zh) * | 2010-06-25 | 2016-05-11 | 瓦西博迪公司 | 同型二聚体蛋白质构建体 |
-
2012
- 2012-12-20 HU HUE12809271A patent/HUE043361T2/hu unknown
- 2012-12-20 CA CA2858963A patent/CA2858963C/en active Active
- 2012-12-20 EP EP12809271.5A patent/EP2793937B1/en active Active
- 2012-12-20 RU RU2014129788A patent/RU2644201C2/ru active
- 2012-12-20 US US14/365,536 patent/US9901635B2/en active Active
- 2012-12-20 EP EP19166523.1A patent/EP3533462A1/en not_active Withdrawn
- 2012-12-20 BR BR112014015016-8A patent/BR112014015016B1/pt active IP Right Grant
- 2012-12-20 KR KR1020147020468A patent/KR102057265B1/ko active Active
- 2012-12-20 ES ES12809271T patent/ES2730718T3/es active Active
- 2012-12-20 CN CN201280064089.7A patent/CN104039833B/zh active Active
- 2012-12-20 PT PT12809271T patent/PT2793937T/pt unknown
- 2012-12-20 TR TR2019/08199T patent/TR201908199T4/tr unknown
- 2012-12-20 AU AU2012356969A patent/AU2012356969B2/en active Active
- 2012-12-20 JP JP2014548019A patent/JP6258864B2/ja active Active
- 2012-12-20 WO PCT/EP2012/076404 patent/WO2013092875A1/en not_active Ceased
- 2012-12-20 DK DK12809271.5T patent/DK2793937T3/da active
-
2014
- 2014-06-18 IL IL233217A patent/IL233217B/en active IP Right Grant
- 2014-06-19 ZA ZA2014/04516A patent/ZA201404516B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015508284A (ja) | 2015-03-19 |
| IL233217B (en) | 2019-05-30 |
| EP2793937A1 (en) | 2014-10-29 |
| AU2012356969B2 (en) | 2017-05-04 |
| CA2858963A1 (en) | 2013-06-27 |
| KR20140107569A (ko) | 2014-09-04 |
| HUE043361T2 (hu) | 2019-08-28 |
| CN104039833A (zh) | 2014-09-10 |
| RU2014129788A (ru) | 2016-02-10 |
| BR112014015016B1 (pt) | 2023-10-03 |
| PT2793937T (pt) | 2019-06-05 |
| EP2793937B1 (en) | 2019-04-10 |
| ES2730718T3 (es) | 2019-11-12 |
| US9901635B2 (en) | 2018-02-27 |
| CA2858963C (en) | 2023-05-23 |
| JP6258864B2 (ja) | 2018-01-10 |
| HK1202442A1 (en) | 2015-10-02 |
| BR112014015016A8 (pt) | 2023-05-09 |
| CN104039833B (zh) | 2018-01-30 |
| KR102057265B1 (ko) | 2019-12-18 |
| AU2012356969A1 (en) | 2014-07-03 |
| EP3533462A1 (en) | 2019-09-04 |
| US20150306217A9 (en) | 2015-10-29 |
| IL233217A0 (en) | 2014-08-31 |
| DK2793937T3 (da) | 2019-07-01 |
| WO2013092875A1 (en) | 2013-06-27 |
| NZ626124A (en) | 2016-07-29 |
| ZA201404516B (en) | 2017-04-26 |
| BR112014015016A2 (pt) | 2020-10-27 |
| RU2644201C2 (ru) | 2018-02-08 |
| US20150056197A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201908199T4 (tr) | HPV'ye karşı aşılar. | |
| EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
| EA201170965A1 (ru) | Усовершенствованные вакцины вируса человеческой папилломы и способы их использования | |
| MX2015005505A (es) | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. | |
| SG131116A1 (en) | Functional influenza virus-like particles (vlps) | |
| EA201992282A1 (ru) | Усовершенствованные вакцины против вируса папилломы человека и способы их применения | |
| EP2589604A4 (en) | SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS | |
| EP2568289A3 (en) | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies | |
| RU2019107976A (ru) | Композиция вакцины | |
| WO2008034388A8 (en) | Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof | |
| BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
| IN2015DN02546A (enExample) | ||
| JP2015533376A5 (enExample) | ||
| NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| JP2010506926A5 (enExample) | ||
| Tai et al. | An mRNA vaccine against monkeypox virus inhibits infection by co-activation of humoral and cellular immune responses | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| WO2013006401A3 (en) | Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2 | |
| UA98254C2 (ru) | мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека | |
| BR112013030150A2 (pt) | proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma |